According to the Yian Technology announcement, the company's second implantable medical magnesium orthopedic device product, the degradable magnesium interface screw, has so far completed the enrollment of all 130 subjects according to the clinical trial plan. More than 70 cases have been followed up for one year after surgery, and the results are in line with previous assumptions. After obtaining the summary report, the company will submit a registration application, and after approval, it can produce and sell. However, product approval and sales are uncertain, and the impact on performance cannot be predicted.

According to the Yian Technology announcement, the company's second implantable medical magnesium orthopedic device product, the degradable magnesium interface screw, has so far completed the enrollment of all 130 subjects according to the clinical trial plan. More than 70 cases have been followed up for one year after surgery, and the results are in line with previous assumptions. After obtaining the summary report, the company will submit a registration application, and after approval, it can produce and sell. However, product approval and sales are uncertain, and the impact on performance cannot be predicted.